Recombinant Humanized (from mouse) antibody to Human PDCD1. It is a drug that targets the programmed cell death 1 (PD-1) receptor. The drug is intended for use in treating metastatic melanoma.
Figure 1 Anti-PDCD1 treatment has significant therapeutic activity against central nervous system lymphoma in an immunocompetent A20 model.
Murine anti-PDCD1 was administered intraperitoneally weekly at 200 ug for 7 weeks, starting at day 8 post-implantation. Anti-PDCD1 treatment had significant impact on tumour growth.
Figure 2 Anti-PDCD1 treatment results in significantly increased infiltration of brain tumour as well as non‐tumour bearing brain by CD8+ lymphocytes in immunocompetent A20 central nervous system lymphoma model.
Immunohistochemistry shows a significant increase in CD8⁺ lymphocyte infiltration of the tumour and the non‐tumour bearing contralateral brain with anti‐PDCD1 treatment compared to no‐treatment control (40×magnification for tumour; 20× magnification for contralateral brain).
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Pembrolizumab.